Portland, OR
Ketamine Therapy clinics in Portland
Portland has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Oregon legalized supervised psilocybin but ketamine is separately regulated as Schedule III and requires a DEA registered prescriber. Most Portland clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Portland only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Portland, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Portland sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable Portland ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Synaptic Institute
- Ketamine Therapy
- Psychedelic Therapy
- Hormone Replacement Therapy (HRT)
Greenbrook Mental Wellness Centers
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
Depression Treatment Clinic Portland- BestMind Behavioral
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
Regulatory context
A note on Oregon's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Oregon Measure 109 / Psilocybin Services Act (2020, operational January 2023)
Established the nation's first regulated psilocybin therapy framework, with state-licensed Service Centers, Facilitators, manufacturers, and testing laboratories overseen by the Oregon Health Authority Psilocybin Services Section. -
Measure 110 / Drug Addiction Treatment and Recovery Act (2020, partially repealed 2024)
Decriminalized personal possession of small amounts of all drugs including psilocybin and MDMA; partially repealed in 2024 re-criminalizing possession as a misdemeanor. -
Oregon Uniform Controlled Substances Act
Mirrors federal scheduling outside the Psilocybin Services framework.
Oregon Psilocybin Services centers have been operational since 2023, with facilitators and service centers licensed statewide. The Oregon Health Authority Psilocybin Services Section oversees licensure, product testing, facilitator training, and facility standards. Federal psilocybin Schedule I status remains unchanged, but DEA has not brought enforcement actions against Measure 109-compliant operations to date. The Oregon Medical Board regulates ketamine prescribing.